C-Suite Speaks

Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second

The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.  

Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics

John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.  

Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.    

In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease. 

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline. 

Key insights from the recent the BIO International Convention in San Diego, US.  

The CEO of Xbrane Biopharma, a Swedish firm focused solely on biosimilar development using a partnered model to potentially take its biosimilars across the globe, speaks exclusively to Generics Bulletin about its ambitions and challenges, including the recent setback for its proposed Lucentis biosimilar in the US.